Connect with us

News

Polish distributor to receive first shipment of medical cannabis

Poland has one of the largest populations of medical cannabis patients in Europe with close to 10,000 legal patients.

Published

on

med4can poland

A Polish medical cannabis distributor, Can4Med is expecting to receive its first shipment of medical-grade cannabis products which will be distributed to pharmacies across Poland.

Can4Med has announced today that it is expecting its first shipment of medical-grade cannabis for purposes of distribution in Poland. The company is set to distribute the products to an “extensive network” of pharmacy partners throughout the country.

Poland has one of the largest populations of medical cannabis patients in Europe with close to 10,000 patients legally accessing a prescription. While the demand is continuing to rise since the legalisation of medical cannabis in 2017, the country continues to face a supply issue as regulation fails to keep up with the developing industry.

Can4Med is a pharmaceutical wholesaler specialising in the acquisition, registration and distribution of medical cannabis and products containing THC and other cannabinoids in Poland. The company holds a general pharmaceutical wholesaler license which permits the marketing and distribution of narcotics for medical purposes and allows the wholesaling of medicinal products and pharmaceutical raw materials for pharmacy prescriptions.

“This significant milestone marks a major step forward in providing pharmacies and patients with regular access to cannabis for medical purposes. Can4Med is actively growing its supply contracts to provide approved products to the Polish market,” said Can4Med CEO Arek Piotrowicz.

Can4Med said it is well-positioned to register and distribute cannabis products throughout Poland. The company has a fully established partnership with a German licensed narcotics wholesaler allowing for the fluid trade of products through Poland and Germany.

Polish legislation allows doctors to prescribe medical cannabis products to patients who can then access them through registered pharmacies. On some specific occasions, products can be covered under public health insurance.

Cannabis products in Poland must be approved by government regulators before being made available for distribution, with six strains of medical cannabis currently approved. Currently, Poland imports all of its medical cannabis products from Germany, Canada and Denmark but the industry has called for changes to legislation that will help strengthen its national supply.

Earlier this year, a number of draft laws were proposed to bolster the country’s medical cannabis industry but were rejected by Parliament.

Markets and industry

Panaxia to expand its Malta production plant with $6m investment

Panaxia’s investment in the country is a “milestone” for Malta’s medical cannabis industry, says Minister for the Environment, Energy and Enterprise.

Published

on

Panaxia to expand its Malta production plant with $6m investment
Home » News » Polish distributor to receive first shipment of medical cannabis

Israel-based Panaxia is set to expand its medical cannabis production facility in Malta and will export its first products to Germany in the coming weeks.

Panaxia is set to deepen its connection with Malta as it plans a further expansion to its local production plant now the company has obtained its EU-GMP licence. 

The company received an official license from the health authorities in Malta to manufacture finished medical cannabis products in May, 2022.

The news of Panaxia’s $6m (~£4.95m) investment was announced during a visit to Panaxia’s Ħal Far plant by Malta’s Minister for the Environment, Energy and Enterprise Miriam Dalli. 

Read more: Panaxia to exit cannabis activities in Israel and focus on Europe

Panaxia aims to enrich the Maltese production portfolio with products aimed for both Europe and Latin American markets. To do this, its Malta facility will diversify into an array of products ranging from the production of tablets, oil and extracts, as well as carrying out clinical trials, stability experiments and research and development.

Minister Miriam Dalli described Panaxia as an early success story for one of Malta’s newest economic niches.

Read more: Panaxia to begin medical cannabis production in Malta

Minister Dalli commented: “Malta Enterprise has been in discussions with Panaxia since the early days after the enacted legislation in 2018. Today, Panaxia is only marking the start of its actual production, but it is already planning an expansion in its facilities. 

“This is another milestone reached for our medical cannabis industry – an industry which further enriches our wider pharmaceutical sector. Malta is the ideal location for such operations, whereby specialised products are developed for the global healthcare supply chain.”

CEO of Panaxia, Dadi Segal, commented: “I am impressed with the role of Malta Enterprise in their support to our Malta team at Panaxia on various levels, not just the financial assistance but also the constant communication and facilitation. 

“We had to build this facility from scratch and the process was long but soothed through Malta Enterprise’s constant guidance.”

Panaxia also operates from locations within the United States, Canada and South Africa, and is currently in the process of registering products in Portugal, Greece, Poland and Brazil amongst others. Its range of pharmaceutical products, over 60 in all, are mainly based on cannabis plant extracts and treat a variety of ailments including nausea, anxiety and depression.

Continue Reading

News

Groundbreaking agreement to supply Czech patients with cannabis extracts

The agreement will enable Czech pharmacies to prepare personalised medicines for patients.

Published

on

Groundbreaking agreement to supply Czech patients with cannabis extracts
Home » News » Polish distributor to receive first shipment of medical cannabis

Prague-based pharmaceutical company, Motagon, will be the first company in the Czech Republic to supply medical cannabis extracts to patients.

Motagon has secured the agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers Phcann International. 

Phcann International is an EU-GMP vertically integrated, multinational pharmaceutical cannabis company headquartered in Warsaw, Poland with an established footprint portfolio of countries like UK, Germany, Poland, Italy, Israel, Portugal, Australia and Brazil.

Read more: Cannabis extract registered in Poland by Curaleaf International

Through the agreement, Czech cannabis patients will now be able to access Motagon’s dried cannabis flowers and extracts to treat a number of health conditions including neuropathic pain, spasticity in multiple sclerosis, chronic pain, vomiting and nausea in the context of conventional cancer treatment, complex palliative care, or treatment of symptoms in neurological diseases such as Parkinson’s.

Additionally, Czech doctors are extended the option to work with an effective form of cannabis medicines, namely standardised extracts with more precise doses of CBD and THC cannabinoids. 

Read more: GROW expands into Germany with launch of medical cannabis extracts

With the extracts, pharmacies will be able to prepare personalised medicines for specific patients, including creams and gels for topical application, oils and capsules for oral consumption and rectal and vaginal suppositories.

Motagon’s chairman and executive director of Heaton, Motagon’s parent company, Jaromír Frič, commented: “We are extremely pleased that in a relatively short period of time we have managed to commence the import, sale and distribution of high-quality medical cannabis to pharmacies in the form of dried flowers, but our aim from the start was to offer more effective forms such as extracts to Czech patients as soon as possible.

“I believe that doctors and especially patients will appreciate this fundamental change, as well as the fact that there will be a broad extracts portfolio with a wide array of THC-CBD formulations, targeting a wider range of patients. 

“I would also like to express my great appreciation to our team at Motagon who have successfully managed to comply with all the legislative requirements of the regulatory authorities.”

Motagon CEO Jan Mehner, has stated that the range of extracts on offer should cover the needs of the vast majority of cannabis patients in the Czech Republic:.

Mehner commented: “We plan to immediately introduce extracts with high THC content and a group of balanced THC-CBD extracts, allowing us to target patient populations that aren’t responding to treatments from existing traditional medicines. 

“We’ll then broaden our portfolio (and patient base) to include high CBD and balanced products with a slight predominance of THC or, conversely, CBD.”

Phcann International CEO, Zlatko Keskovski, commented: “The agreement with Motagon will provide both companies with the first mover advantage in the Czech market where we will be able to set and implement the highest standards of quality and consistency that will meet expectations of the Czech patients.”

The first cannabis extracts are expected to be available in Czech pharmacies as early as September 2022.

Continue Reading

CBD

Swiss CBD investment company secures £26.23m funding

Pharma Tech Holding has obtained a capital commitment agreement from LDA Capital.

Published

on

Swiss CBD investment company secures £26.23m funding
Home » News » Polish distributor to receive first shipment of medical cannabis

Pharma Tech Holding SA has secured a CHf30m (£26.23m) investment from global investment group LDA Capital Ltd – with expertise in cross-border transactions including the agriculture, Agri-tech, and CBD industries – which will support its portfolio investments.

Pharma Tech Holding SA invests in innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, agri-tech, and functional food.

The CHf30m investment from LDA Capital will allow the company to invest and support its portfolio company Blue Sky Swisse SA, which focuses on the extraction of natural active principles from vegetable matrices, vegetable waste, and renewable sources to deliver B2B products under the form of CBD oil, terpenes and waxes. 

Read more: New cannabis-themed ETF launches

The factory, located in Biasca, will be built with state of art of extraction technology using supercritical CO2, and will be self-sufficient through the use of solar photovoltaic panels and district heating. 

CEO at Pharma Tech Holding, Sabina Del Nigro, commented: “We’re thrilled with this partnership and are so glad that LDA Capital recognises the value of Pharma Tech Holding and its portfolio company, with the aim of creating one of the most innovative hubs for health-tech, agri-tech and functional food.”

Blue Sky Swisse will make high-quality CBD due to a proprietary extraction process, starting from the farming, performed under strict control and culminating with the immediate freezing of the flowers after harvest. 

It will also sell “all natural” formulations to increase bioavailability and will invest in the agricultural raw material chain, as well as creating an aeroponic greenhouse in Ticino, to deliver a high-quality GMP pharmaceutical CBD oil.

LDA Capital agreed to commit an amount of up to CHf30m in cash within a maximum of three years. This Capital Commitment will be released based on drawdowns by Pharma Tech Holding, which Pharma Tech Holding has the right to exercise at its sole discretion.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]